SXTC

China SXT Pharmaceuticals Inc
NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$2.20M
P/E Ratio
EPS
$-7.55
Beta
1.82
52W High
$312.00
52W Low
$0.05
50-Day MA
$1.94
200-Day MA
$70.67
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About China SXT Pharmaceuticals Inc

China SXT Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the research, development, manufacture, marketing and sale of Traditional Chinese Medicine Tablets (TCMP) in China. The company is headquartered in Taizhou, China.

Official WebsiteChinaFY End: March

Fundamentals

Revenue (TTM)$1.14M
Gross Profit (TTM)248,700
EBITDA$-7.05M
Operating Margin-153.30%
Return on Equity-27.50%
Return on Assets-15.80%
Revenue/Share (TTM)$1.67
Book Value$31.01
Price-to-Book0.09
Price-to-Sales (TTM)1.93
EV/Revenue43.06
EV/EBITDA7.08
Quarterly Earnings Growth (YoY)42.60%
Quarterly Revenue Growth (YoY)-43.90%
Shares Outstanding$38.22M
Float$31.94M
% Insiders82.57%
% Institutions0.18%

Historical Volatility

HV 10-Day
162.60%
HV 20-Day
147.44%
HV 30-Day
154.20%
HV 60-Day
119.80%
HV Rank

Volatility is currently expanding

Latest News

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.

GlobeNewsWire7/24/2026Neutral
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

TAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4,500,000 units (each, a “Unit”), consisting of one Class A ordinary share of the Company, no par value per share (each, a “Class A ordinary share”), and one common warrant (each, a “Warrant”), at a purchase price of $2.00 per Unit in a registered direct offering.

GlobeNewsWire7/23/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SXTC and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026